Catalent Zydis® & OSDrC® OptiDoseTM Technologies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

 

Catalent Zydis® & OSDrC® OptiDoseTM Technologies

Catalent's Zydis® orally disintegrating tablet (ODT) fast-dissolve formulation, is a unique, freeze-dried oral dosage form that disperses instantly in the mouth, requiring no water. This may enhance the performance and may also contribute towards better patient compliance.
With more than 20 products launched in 50 countries, Zydis is the world's best in class ODT technology. Whether to advance pharmacokinetics through pre-gastric absorption, improve patient compliance, or add marketing advantage to a valued brand, Catalent's customers draw on Zydis fast dissolve technology to potentially enhance investment value and accelerate a product’s potential.

Catalent’s OSDrC® OptiDose™ is an innovative, flexible core tableting technology that enables the formulation and manufacturing of single or multi-cored tablets with differentiated controlled release functionality and a range of unique dose forms, including fixed dose combination tablets.

With shown improvement in mass variability between layers, OptiDose offers tablet design, minimising cross-layer interaction and improving product stability.

In 2014, Catalent will celebrate 80 years of softgel manufacturing and has continually delivered innovation with specialised global manufacturing and innovative technological enhancements such as gelatin-free encapsulation, chewable softgels and enteric coatings, to enable delayed-release of the active ingredient with targeted absorption.

Company name:  Catalent Pharma Solutions

Website: www.catalent.com

E-mail: info@catalent.com
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
FindPharma Custom Search

Click here